Amgen 
Welcome,         Profile    Billing    Logout  
 160 Products   813 Diseases   160 Products   1552 Trials   75151 News 


«12345678910111213...858859»
  • ||||||||||  Tibsovo (ivosidenib) / Servier
    Enrollment closed, Enrollment change, Trial primary completion date:  Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) -  Jan 13, 2025   
    P1,  N=2, Active, not recruiting, 
    Our data suggest that HBV replication enhances the stemness and drug resistance of HCC, providing a strong theoretical foundation for the development of targeted and efficient treatments for HBV-infected HCCs. Recruiting --> Active, not recruiting | N=25 --> 2 | Trial primary completion date: Dec 2026 --> Jan 2025
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Long-Term Efficacy and Safety of Denosumab: Insights beyond 10 Years of Use. (Pubmed Central) -  Jan 13, 2025   
    In certain scenarios, such as advanced chronic kidney disease, prolonged denosumab may be required to balance AE risks with fracture prevention benefits. Denosumab shows potential for long-term efficacy in augmenting BMD; however, monitoring for AEs is crucial to guide clinical decision-making effectively.
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  Does early administration of denosumab delay bone healing after intertrochanteric femoral fractures? (Pubmed Central) -  Jan 12, 2025   
    Benralizumab, dupilumab, and tezepelumab have been reported to improve both ECRS and complicated bronchial asthma. Early administration of denosumab after intertrochanteric femoral fracture surgery did not delay radiological or clinical fracture healing times when compared with ibandronate administration.
  • ||||||||||  Prolia (denosumab) / Amgen
    Retrospective data, Review, Journal:  Anti-osteoporotic drug efficacy for periprosthetic bone loss after total hip arthroplasty: A systematic review and network meta-analysis. (Pubmed Central) -  Jan 12, 2025   
    Early administration of denosumab after intertrochanteric femoral fracture surgery did not delay radiological or clinical fracture healing times when compared with ibandronate administration. Bisphosphonate and denosumab may be effective anti-osteoporotic drugs for preventing periprosthetic proximal femoral bone loss due to stress shielding after THA, particularly in cementless proximal fixation stems, which are the most commonly used prostheses worldwide.
  • ||||||||||  Prolia (denosumab) / Amgen
    Review, Journal:  Current and emerging bone resorption inhibitors for the treatment of osteoporosis. (Pubmed Central) -  Jan 12, 2025   
    Critical pathways and key molecules that mediate regulation of bone resorption have been identified. These factors may underpin novel therapeutic avenues for osteoporosis, but their potential for translation into clinical applications is yet to be tested.
  • ||||||||||  Review, Journal:  Topical and Intralesional Treatments for Skin Metastases and Locoregionally Advanced Melanoma. (Pubmed Central) -  Jan 12, 2025   
    Brief comments on other alternatives in development such as interferon-alpha, interleukin-12, ipilimumab and intralesional daromun are presented...It has also been described in a few papers that non-injected lesions may respond after the application of a local therapy in distant skin-metastases. Many of these intralesional treatments are being combined in different investigations with systemic immunotherapies, with the aim of obtaining synergic responses in those patients with refractory disease.
  • ||||||||||  Ibrance (palbociclib) / Pfizer, giredestrant (GDC-9545) / Roche
    Journal:  Transformer-based modeling of Clonal Selection and Expression Dynamics reveals resistance mechanisms in breast cancer. (Pubmed Central) -  Jan 12, 2025   
    Clustering based on partial least squares regression found that high baseline expression of both SNHG25 and SNCG genes was the primary marker of positive selection to co-treatment and thus potentially associated with innate resistance - an aspect that traditional differential analysis methods missed. In conclusion, TraCSED enables associating features with phenotypes in a time-dependent manner from scRNA-seq data.
  • ||||||||||  acetylcysteine solution / Generic mfg., SB202190 / Amgen
    Journal:  Cigarette smoke extract induces p38-mediated expression and ROS/rho-mediated translocation of alpha 2C adrenoceptor in human microvascular smooth muscle cells. (Pubmed Central) -  Jan 12, 2025   
    This increase is associated with the activation of p38 MAPK, as pretreatment with SB-202190, a p38 specific inhibitor, attenuated CSE-induced ?2C-AR expression...We also show that CSE induces translocation of vascular ?2C-AR to the plasma membrane, and that this mobilization is attenuated by inhibiting ROS via N-acetylcysteine or apocynin...While CSE activates a p38-dependent mechanism to increase ?2C-AR expression, it initiates the receptor's spatial and functional rescue via a ROS/RhoA signaling pathway. These results provide mechanistic insight into the effect of cigarette smoking on RP, and further reinforce that smoking avoidance/cessation is critical to manage this disease, especially in the absence of a definitive drug for RP.
  • ||||||||||  Mustargen (mechlorethamine) / Recordati, SB202190 / Amgen
    Journal:  Mustard Gas Induced Corneal Injury Involves Ferroptosis and p38 MAPK Signaling. (Pubmed Central) -  Jan 12, 2025   
    A p38 MAPK specific inhibitor, SB202190, was also used...The inhibition of p38 MAPK promoted cell survival and reduced ROS production following mustard gas exposure. The results of in vivo and in vitro investigations uncovered a novel mechanism that mustard gas toxicity to the cornea involves ferroptosis pathway and p38 MAPK activation.
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Journal:  Roseomonas cutis sp. nov., isolated from human epidermis. (Pubmed Central) -  Jan 12, 2025   
    Considering the chemotaxonomic, genotypic and phenotypic features, as well as the low average nucleotide identity and digital DNA-DNA hybridization values compared to its closest phylogenomic neighbours, OT10T is proposed to be a novel species named Roseomonas cutis sp. nov., with OT10T designated as the type strain (=KCTC 92087T =JCM 34968T).
  • ||||||||||  Prolia (denosumab) / Amgen
    Journal:  The Effect of Denosumab on Pain and Radiological Improvement in Giant Cell Tumours of the Spine in the Acute Setting. (Pubmed Central) -  Jan 12, 2025   
    This study provides necessary insight to the limited literature on the use of denosumab for spinal GCT in the acute phase. The clinical and radiographic responses observed demonstrate the critical role that neo-adjuvant denosumab has by reducing the tumour burden around critical adjacent neurovascular structures before eventual resection, significant pain improvement even with presence of fractured vertebra.
  • ||||||||||  Journal:  Drugs for age-related macular degeneration. (Pubmed Central) -  Jan 12, 2025   
    This network meta-analysis demonstrates that T-VEC may be a favorable choice of treatment for metastatic melanoma. No abstract available
  • ||||||||||  Neupogen (filgrastim) / Kyowa Kirin, Amgen
    Journal:  Drug Development. (Pubmed Central) -  Jan 12, 2025   
    No abstract available Outcomes of the current study suggest neuroprotective potential of filgrastim and its ability to correct movement disability and thus could prove to be useful candidate molecule in the management of motor disorders.
  • ||||||||||  Nplate (romiplostim) / Amgen, Promacta (eltrombopag) / Novartis
    Journal:  Thrombopoietin Receptor Agonists for Thrombocytopenia in Pediatric Hematologic Malignancies. (Pubmed Central) -  Jan 12, 2025   
    TPO-RAs were effective in managing refractory thrombocytopenia in pediatric and young adult patients being treated for hematologic malignancies, with a favorable safety profile, even among patients with multiple comorbidities. These findings warrant further investigation through prospective clinical trials to confirm efficacy and establish clinical guidelines for this population.
  • ||||||||||  Tepezza (teprotumumab-trbw) / Roche, Amgen
    Journal:  Observational Characterization of the Retreatment Course of Patients With Thyroid Eye Disease. (Pubmed Central) -  Jan 12, 2025   
    Understanding these factors could help predict which patients may require retreatment or chronic dosing with teprotumumab. Further studies are essential to advance our understanding of the immunomodulatory effects of teprotumumab, duration of its therapeutic benefit, and potential retreatment strategies to improve long-term patient outcomes.
  • ||||||||||  Prolia (denosumab) / Amgen, Orkedia (evocalcet) / Mitsubishi Tanabe
    Journal:  Severe hypophosphataemia following denosumab administration successfully managed using a calcimimetic agent. (Pubmed Central) -  Jan 12, 2025   
    Evocalcet contributed to the normalised parathyroid hormone and phosphorus levels, allowing the discontinuation of phosphorus supplementation. This case highlights the complexity of managing electrolyte imbalances induced by bone-modifying agents, such as denosumab, underscoring the importance of monitoring bone metabolism markers and the potential effectiveness of evocalcet in managing drug-induced secondary hyperparathyroidism and hypophosphataemia.
  • ||||||||||  Prolia (denosumab) / Amgen, zoledronic acid / Generic mfg.
    Journal:  Clinical experience with denosumab discontinuation. (Pubmed Central) -  Jan 12, 2025   
    Adhering to the recommendation in the ECTS position statement, a mean of 3 infusions of ZOL limited the bone loss 12 and 24 months after DMAb discontinuation, thereby preserving most of the BMD gained during DMAb treatment. The frequent occurrence of flu-like symptoms after ZOL proves to be a challenge, showing that routine prophylaxis against acute phase responses should be considered in patients treated with ZOL after discontinuing DMAb.
  • ||||||||||  Prolia (denosumab) / Amgen
    Clinical data, Retrospective data, Journal:  Denosumab and clinical outcomes among men with osteoporosis: a retrospective cohort study. (Pubmed Central) -  Jan 12, 2025   
    No abstract available In this large, real-world study evaluating denosumab treatment among men with osteoporosis, the observed fracture risk reductions were consistent with the available risk reductions demonstrated in clinical trials among women with postmenopausal osteoporosis.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Journal:  Enhanced radiotherapy susceptibility in NSCLC through palbociclib-mediated PP5 inhibition. (Pubmed Central) -  Jan 11, 2025   
    Our findings provide compelling evidence that targeting PP5 can significantly enhance the therapeutic outcomes of radiotherapy in NSCLC. This research offers valuable insights into new combination therapy strategies, highlighting the potential of PP5 as a novel therapeutic target to overcome radioresistance.